telomere and telomerase: from discovery to cancer treatment

conclusions since telomerase is expressed in 90% of cancer cells, its inhibition can be considered as a goal of cancer treatment. results about 90% of cancers need a high level of this enzyme to continue cell multiplication. since this enzyme set is absent in normal cells, or present at a very low level, use of telomerase inhibitors cannot have significant effects on normal cells. evidence acquisition telomeres are terminal structures of linear chromosomes in eukaryotes and consist of multiple repetitive sequences. their main function is to protect and confer stability to chromosome ends and prevent their breakage, end-to-end fusion, and degeneration. polymerases responsible for replication of dna in eukaryotes are not able to replicate chromosome ends and, during cell division, chromosomes continuously become shorter from the telomere ends. this shortening will eventually stop cell division. in cancer cells, there is a ribonucleoprotein enzyme called telomerase that allows compensation of telomere shortening and continuation of the cell multiplication process. context cancer is a major cause of death worldwide. it was estimated that 7.6 million people died during 2008 due to cancer and this figure is expected to double by 2030. to conquer this disease, discovery of validated targets and new drugs is a necessity.